EGFR and non-small cell lung carcinoma: A meta-analysis evaluating the efficacy of afatinib in patients with NSCLC and brain metastases has also been reported; 448 patients with brain metastases were divided into the control (chemotherapy and first-generation EGFR-TKIs) and afatinib groups.